---
title: Classical chemotherapy, immunotherapy, or adjuvant radiotherapy-how to improve
  the oncologic outcome of radical cystectomy?
date: '2024-09-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39285097/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240917194252&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: According to current guidelines, patients with muscle-invasive urothelial
  carcinoma (pT2-pt4a pN0) should be offered neoadjuvant cisplatin-containing chemotherapy
  before radical cystectomy. If not used neoadjuvantly, chemotherapy can be administered
  in the adjuvant setting (for > pT3 or pN+ disease). Both neoadjuvant and adjuvant
  therapy lead to improved overall survival. In the adjuvant setting, the checkpoint
  inhibitor nivolumab has also been approved for treatment of PD-L1-positive ...
disable_comments: true
---
According to current guidelines, patients with muscle-invasive urothelial carcinoma (pT2-pt4a pN0) should be offered neoadjuvant cisplatin-containing chemotherapy before radical cystectomy. If not used neoadjuvantly, chemotherapy can be administered in the adjuvant setting (for > pT3 or pN+ disease). Both neoadjuvant and adjuvant therapy lead to improved overall survival. In the adjuvant setting, the checkpoint inhibitor nivolumab has also been approved for treatment of PD-L1-positive ...